Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomised, Active Controlled Multi-center Phase II Dose Finding Study to Evaluate the Ability of PA21 to Lower Serum Phosphate Levels and the Tolerability in Patients With Chronic Kidney Disease on Maintenance Hemodialysis

NCT00824460 is registered in ClinicalTrials.gov with Vifor Pharma as lead sponsor.

NCT NCT00824460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00824460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomised, Active Controlled Multi-center Phase II Dose Finding Study to Evaluate the Ability of PA21 to Lower Serum Phosphate Levels and the Tolerability in Patients With Chronic Kidney Disease on Maintenance Hemodialysis
Lead sponsor
Vifor Pharma
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2008
Completion date
March 31, 2010
Enrollment
154 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease